Midodrine During Recovery From Septic Shock

Northwell Health

Status and phase: Withdrawn; Phase 4

Conditions: Hypotension; Shock, Septic; Sepsis

Treatments: Drug: placebo; Drug: Midodrine

Study type: Interventional

Funder types: Other

Identifiers

NCT02771158

temp-1187

Details and patient eligibility

About

The purpose of this study is to determine whether midodrine administration decreases duration of intravenous vasopressors and intensive care unit length of stay for patients in septic shock.

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• admitted to intensive care unit
• diagnosis of septic shock on intravenous vasopressors
• stable/decreasing doses of intravenous vasopressors
• stable/improving organ function

Exclusion criteria

• allergy to midodrine
• multiple intravenous vasopressors
• increasing intravenous vasopressor requirements
• worsening organ dysfunction
• severe bradycardia

Trial design

Primary purpose: Supportive Care

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

0 participants in 2 patient groups, including a placebo group

midodrine

Experimental group

Description:

randomization to midodrine 20 mg every 8 hours to be increased to a maximum of 40 mg every 8 hours until intravenous vasopressor discontinuation

Treatment:

Drug: Midodrine

placebo

Placebo Comparator group

Description:

randomization to placebo control

Treatment:

Drug: placebo